Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for UNCY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 14.44M
March 31, 2026 19.57M
December 31, 2025 6.606M
September 30, 2025 26.33M
June 30, 2025 10.98M
March 31, 2025 2.546M
December 31, 2024 0.365M
September 30, 2024 -0.157M
June 30, 2024 -0.811M
March 31, 2024 45.69M
December 31, 2023 -0.205M
September 30, 2023 -0.051M
June 30, 2023 0.00
March 31, 2023 27.80M
Date Value
December 31, 2022 -0.471M
September 30, 2022 0.00
June 30, 2022 0.00
March 31, 2022 0.00
December 31, 2021 0.00
September 30, 2021 21.48M
June 30, 2021 0.071M
March 31, 2021 0.82M
December 31, 2020 0.475M
September 30, 2020 0.768M
June 30, 2020 0.141M
March 31, 2020 0.06M
December 31, 2019 0.463M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Ironwood Pharmaceuticals, Inc. -199.70M
Theriva Biologics, Inc. -0.014M
AbbVie, Inc. -5.054B
Decoy Therapeutics, Inc. 3.163M
Nkarta, Inc. 0.676M